KemPharm, Inc. Reports Third Quarter 2018 


Company announced positive topline results from KP415.E01 efficacy and safety trial in children with attention deficit hyperactivity disorder (ADHD) 
Announced positive topline results from the oral and intranasal human abuse potential (HAP) trials of KP415 Prodrug; successfully completed KP415 Presented data from the intranasal and intravenous HAP trials of KP415 Prodrug at the American Academy of Child & Adolescent Psychiatry meeting 
Net loss of $0.94 per basic and diluted share for the quarter ended September 30, 2018, compared to net loss of $0.68 per basic and diluted share for …

[Read on via official release]

Source: US SEC
View full document: